Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Potential direct anti-inflammatory mechanisms from preclinical and early clinical studies include: Modulation of immune cell function : GLP-1 receptor activation may reduce pro-inflammatory cytokine production from macrophages and other immune cells Reduction of oxidative stress : These medications may decrease reactive oxygen species production, which contributes to inflammatory processes Endothelial protection : GLP-1 receptor agonists may improve endothelial function and reduce vascular inflammation Inhibition of inflammatory signalling pathways : Including suppression of nuclear factor-kappa B (NF-B), a key regulator of inflammatory gene expression It's important to note that many of these mechanisms have been primarily demonstrated in laboratory or animal studies, with more limited evidence in humans
Read: Catalent x Novo: the GLP-1 wars heat up What are GLP-1 agonists
The trial period was 12 weeks and the dose was 60 mg/kg/day in three doses with a maximum of 4,200 mg/day
Optimised Digestive SupportIncludes DigeZyme digestive enzymes to promote efficient protein digestion and nutrient utilisation, minimising digestive discomfort
What is Strive Pharmacy
Research suggests that baseline glutathione levels decline with age and metabolic stress, which may impact resilience to oxidative burden
